Caleres is a St. Louis-based market-leading portfolio of consumer-driven footwear brands that operates the Famous Footwear retail chain and the brand portfolio that includes Sam Edelman, Naturalizer, Allen Edmonds, Dr. Scholl's, Stuart Weitzman, and the broader set of owned and licensed footwear brands, and the company is in the middle of a fiscal first quarter that demonstrates the kind of brand-portfolio recovery the footwear retail cohort has been waiting for. Q1 FY2026 net sales of $666.6 million were 8.5 percent above the prior-year quarter, with the Brand Portfolio sales increasing 20.6 percent (organic up 5.8 percent) and the Famous Footwear sales declining 2.5 percent. The Q1 FY2026 GAAP EPS of $0.42 was above guidance, and the Q1 FY2026 Adjusted EPS of $0.38 was also above guidance, with the brand portfolio momentum and the gross margin expansion of 200 basis points driving the outperformance. The combination of the 8.5 percent revenue growth, the 200 basis points of gross margin expansion, the brand portfolio outperformance, and the disciplined execution is the cleanest single-sentence read on what the footwear portfolio business model is producing, and the combination is the source of the operating-leverage spread the equity offers the buy-side.
The numbers tell the story with the kind of operational detail the footwear retail equity has been waiting for. The Q1 FY2026 Brand Portfolio net sales of approximately $445 million (computed from 20.6 percent increase on prior-year base of approximately $369 million) were 20.6 percent above the prior-year quarter, with the Brand Portfolio organic growth of 5.8 percent reflecting the underlying brand momentum. The Q1 FY2026 Famous Footwear net sales of approximately $221 million (computed from -2.5 percent decline) were 2.5 percent below the prior-year quarter, with comparable sales down 2.3 percent, and the Famous Footwear softness reflects the softer consumer and macroeconomic backdrop.
The Q1 FY2026 gross profit of $315.5 million was 13.2 percent above the prior-year quarter's $278.7 million, with the gross margin of 47.3 percent expanding 200 basis points from the prior-year quarter's 45.4 percent. The 200 basis points of gross margin expansion is the cleanest single read on the favorable mix, the successful tariff mitigation actions, and the disciplined execution the company is producing.
The Q1 FY2026 GAAP earnings per diluted share of $0.42 was above the guidance the company provided, and the Q1 FY2026 Adjusted EPS of $0.38 was also above guidance. The Q1 FY2026 net earnings of $14.3 million were 105.6 percent above the prior-year quarter's $6.9 million. The Q1 FY2026 GAAP operating earnings of $23.9 million were 105.9 percent above the prior-year quarter's $11.6 million.
The Q2 FY2026 guidance is for consolidated net sales up mid-to-high-single digits and GAAP EPS of $0.32 to $0.38. The full-year FY2026 guidance is for consolidated net sales up low-to-mid-single digits and GAAP EPS of $1.44 to $1.69, with adjusted EPS of $1.40 to $1.65 versus the prior guidance of $1.35 to $1.65. The full-year FY2026 guidance is the cleanest single read on the management confidence in the operating profile the company is producing.
The question the next four quarters resolve is whether the company can sustain the brand portfolio momentum and produce the Famous Footwear recovery, and whether the operating-leverage spread is durable through the rest of fiscal 2026. A Q2 FY2026 print that delivers the guided mid-to-high-single digits net sales growth and the $0.32 to $0.38 GAAP EPS would confirm the operating profile is sustainable. A Q2 FY2026 print that misses the guided revenue range or the Famous Footwear recovery does not produce would force the market to reprice the equity for a more modest terminal value.